TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Can't find what you're looking for?
View all search resultsCan't find what you're looking for?
View all search results
In plasma therapy for COVID-19 - which remains in a trial stage - a patient who has recovered from and has antibodies against the virus provides blood plasma to patients with the same blood group, to help speed up the latter's recovery.
The European Union wants to fast-track funding to treat COVID-19 patients with blood plasma collected from survivors, an EU document seen by Reuters shows, in a sign of the bloc's growing confidence in the experimental treatment.
The European Union is seeking firms to supply 24 intensive care drugs, an EU official told Reuters, as it strives to tackle shortages of medicines for COVID-19 patients amid fears of a second wave of infections and strong global demand.
Remdesivir is in high demand after the intravenously-administered medicine helped shorten hospital recovery times in a clinical trial. It is believed to be most effective in treating COVID-19 patients earlier in the course of disease than other therapies like the steroid dexamethasone.
South Korea has added Gilead's anti-viral drug remdesivir to its coronavirus treatment guidelines in its first revision of recommendations since the outbreak began and urged caution in the use of the steroid therapy dexamethasone.
